Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients

Annals of the Rheumatic Diseases

Volumn 73, Issue 5, 2014, Pages 941-943

  Genre, Fernanda ^a   López Mejías, Raquel ^a   Miranda Filloy, José A ^b   Ubilla, Begoña ^a   Carnero López, Beatriz ^c   Gómez Acebo, Inés ^d   Blanco, Ricardo ^a   Ochoa, Rodrigo ^a   Rueda Gotor, Javier ^a   Pina, Trinitario ^a   González Juanatey, Carlos ^b   Llorca, Javier ^d   González Gay, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

^c HOSPITAL EL BIERZO   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; RETINOL BINDING PROTEIN 4;

ADIPOCYTE; ANKYLOSING SPONDYLITIS; CELL ACTIVATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RISK FACTOR;

ANKYLOSING SPONDYLITIS; ANTI-TNF; ATHEROSCLEROSIS; INFLAMMATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DIABETES MELLITUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; RETINOL-BINDING PROTEINS, PLASMA; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898015379     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204484     Document Type: Letter

References (10)

1. Peters MJ, Visman I, Nielen MM, et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010;69:579-81.
2. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine 2009;88:358-65.
3. Heldmann F, Brandt J, van der Horst-Bruinsma IE, et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011;29:672-80.
4. Genre F, Miranda-Filloy JA, López-Mejias R, et al. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients. Ann Rheum Dis 2013;72:1265-7.
5. Miranda-Filloy JA, Llorca J, Carnero-López B, et al. TNF-α antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol 2012;30:850-5.
6. Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-63. (Pubitemid 43882351)
7. Gavi S, Stuart LM, Kelly P, et al. Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. J Clin Endocrinol Metab 2007;92:1886-90. (Pubitemid 46997205)
8. Christou GA, Tselepis AD, Kiortsis DN. The metabolic role of retinol binding protein 4: an update. Horm Metab Res 2012;44:6-14.
9. Genre F, López-Mejias R, Miranda-Filloy JA, et al. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy. Clin Exp Rheumatol 2013 [Epub ahead of print 26 Aug 2013].
10. O'Shea FD, Tsui FW, Chiu B, et al. Retinol (vitamin A) and retinol-binding protein levels are decreased in ankylosing spondylitis: clinical and genetic analysis. J Rheumatol 2007;34:2457-9. (Pubitemid 350230671)